Trial · NCT03283085
Adverse events744
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 744
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Breast pain | Reproductive system and breast disorders | UC: Ontamalimab 25 mg | 0 | 89 | |
| other | Breast pain | Reproductive system and breast disorders | UC: Ontamalimab 25mg Then 75 mg | 1 | 159 | |
| other | Breast pain | Reproductive system and breast disorders | UC: Ontamalimab 75mg | 0 | 268 | |
| other | Breast pain | Reproductive system and breast disorders | CD: Ontamalimab 25 mg | 0 | 5 | |
| other | Breast pain | Reproductive system and breast disorders | CD: Ontamalimab 25 mg Then 75 mg | 1 | 10 | |
| other | Breast pain | Reproductive system and breast disorders | CD: Ontamalimab 75 mg | 0 | 26 | |
| other | Bronchitis | Infections and infestations | UC: Ontamalimab 25 mg | 0 | 89 | |
| other | Bronchitis | Infections and infestations | UC: Ontamalimab 25mg Then 75 mg | 9 | 159 | |
| other | Bronchitis | Infections and infestations | UC: Ontamalimab 75mg | 8 | 268 | |
| other | Bronchitis | Infections and infestations | CD: Ontamalimab 25 mg | 0 | 5 | |
| other | Bronchitis | Infections and infestations | CD: Ontamalimab 25 mg Then 75 mg | 2 | 10 | |
| other | Bronchitis | Infections and infestations | CD: Ontamalimab 75 mg | 0 | 26 | |
| other | C-reactive protein increased | Investigations | UC: Ontamalimab 25 mg | 0 | 89 | |
| other | C-reactive protein increased | Investigations | UC: Ontamalimab 25mg Then 75 mg | 2 | 159 | |
| other | C-reactive protein increased | Investigations | UC: Ontamalimab 75mg | 3 | 268 | |
| other | C-reactive protein increased | Investigations | CD: Ontamalimab 25 mg | 0 | 5 | |
| other | C-reactive protein increased | Investigations | CD: Ontamalimab 25 mg Then 75 mg | 1 | 10 | |
| other | C-reactive protein increased | Investigations | CD: Ontamalimab 75 mg | 0 | 26 | |
| other | Colitis ulcerative | Gastrointestinal disorders | UC: Ontamalimab 25 mg | 22 | 89 | |
| other | Colitis ulcerative | Gastrointestinal disorders | UC: Ontamalimab 25mg Then 75 mg | 21 | 159 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03283085/events?page=4